MediciNova Inc
Cerrado
SectorSanidad
1.78 4.71
Resumen
Variación precio
24h
Mínimo
1.78
Máximo
1.8
Ingresos | -2.3B -2.3B |
|---|---|
Ventas | 271K 458K |
BPA | -0.05 |
Margen de beneficios | -504,786.678 |
Empleados | 6 |
EBITDA | 5.1K -2.5M |
Próximas Ganancias | 10 nov 2026 |
|---|
Capitalización Mercado | 15M 80M |
|---|---|
Apertura anterior | -2.93 |
Cierre anterior | 1.78 |
Noticias sobre sentimiento de mercado
By Acuity
52%
48%
252 / 339 Clasificación en Healthcare
MediciNova Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
MediciNova Inc previsión
Sentimiento
By Acuity
252 / 339 Clasificación en Sanidad
Noticias sobre sentimiento de mercado
Coyuntura bajista
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por encima de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.